EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Secretory Phospholipase A 2 in Patients With Sickle Cell Disease Hospitalized for Vaso‐Occlusive Pain Episodes

Rawan Korman iD, Maria Yasmine, Dunia Hatabah iD, Noor Alzraikat iD, Frank Harris iD, Lou Ann Brown, Satheesh Chonat iD, Nitya Bakshi iD, Chris A Rees iD, Carlton Dampier iD, Claudia R Morris iD

Pediatric Blood & Cancer · 2026-10 · 73 (10)

DOI: 10.1002/1545-5017.70615 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Pediatric Blood & Cancer, online erschienen am 04.08.2026. Verfasst von Rawan Korman und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA. Hauptthemen laut MEDLINE: Anemia, Sickle Cell, Phospholipases A2, Secretory, Acute Chest Syndrome, Arginine. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIH HHS, NHLBI NIH HHS, NCCIH NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Secretory phospholipase A 2 (sPLA 2 ) is an inflammatory mediator linked to acute chest syndrome (ACS) in sickle cell disease (SCD), a serious complication that can develop during an acute vaso‐occlusive pain episode (VOE). Plasma sPLA 2 levels have been proposed as a potential biomarker for predicting ACS onset.

Objective

To assess serial plasma sPLA 2 levels in 105 pediatric patients hospitalized for SCD‐VOE and determine the effects of arginine therapy compared to placebo. Procedures This is a pharmacokinetics/pharmacodynamics and randomized controlled trial of intravenous arginine therapy. Statistical methods included t ‐tests, chi‐square, and correlation analyses.

Results

Mean age was 12.7 ± 3.7 years, 48% were male, 67% had Hb‐SS, and 70% were prescribed hydroxyurea. Using a previously established SCD‐specific cutoff of 48 ng/mL, presenting sPLA 2 levels were elevated in 33% of patients (mean sPLA 2 level 85.7 ± 32.9 ng/mL). SPLA 2 elevation in the emergency department was more common in patients with ACS compared to those without ACS (64% vs. 30%; p = 0.02; negative predictive value of 94%). Peak sPLA 2 levels were significantly higher in febrile ( n = 34) versus afebrile patients ( n = 71;101.0 ± 45.3 vs. 48.7 ± 35.4 ng/mL; p < 0.0001). Among subjects with elevated baseline sPLA 2 , arginine therapy resulted in a significant reduction in sPLA 2 levels by discharge compared to placebo (−27.8 ± 38.1 ng/mL; p = 0.002; n = 23 vs. −15.0 ± 41.2 ng/mL; p = 0.23; n = 12).

Conclusions

SPLA 2 is an underutilized biomarker of ACS given accumulating evidence of its role. In particular, low levels may identify patients at low risk for ACS. Arginine therapy may modulate inflammation in patients with SCD during VOE and/or ACS. Trial Registration ClinicalTrials.gov identifiers: NCT02447874; NCT02536170

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anemia, Sickle CellPhospholipases A2, SecretoryAcute Chest SyndromeArgininePainHumansMaleChildFemaleVaso-Occlusive CrisesAdolescentBiomarkersHospitalization

Stichwörter der Autor:innen

acute chest syndromeargininesickle cell diseasevaso‐occlusive pain episode

Substanzen

Phospholipases A2, SecretoryArginineBiomarkers

Autor:innen und Institutionen

  • Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA.
  • Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, Georgia, USA.
  • Department of Pediatrics, Yale School of Medicine, New Haven, Connecticut, USA.
  • Division of Emergency Medicine, Children's Healthcare of Atlanta, Atlanta, Georgia, USA.

ORCID-Profile: Rawan Korman, Dunia Hatabah, Noor Alzraikat, Frank Harris, Satheesh Chonat, Nitya Bakshi, Chris A Rees, Carlton Dampier, Claudia R Morris

Förderung

  • NIH HHS
  • NHLBI NIH HHS
  • NCCIH NIH HHS
  • United States Food and Drug Administration
  • National Institutes of Health
  • National Center for Complementary and Integrative Health
  • U.S. Food and Drug Administration
  • National Heart, Lung, and Blood Institute

Zitieren

APA

Korman, R., Yasmine, M., Hatabah, D., Alzraikat, N., Harris, F., Brown, L. A., Chonat, S., Bakshi, N., Rees, C. A., Dampier, C., & Morris, C. R. (2026). Secretory Phospholipase A 2 in Patients With Sickle Cell Disease Hospitalized for Vaso‐Occlusive Pain Episodes. Pediatric Blood & Cancer, 73(10). https://doi.org/10.1002/1545-5017.70615

Vancouver

Korman R, Yasmine M, Hatabah D, Alzraikat N, Harris F, Brown LA, et al. Secretory Phospholipase A 2 in Patients With Sickle Cell Disease Hospitalized for Vaso‐Occlusive Pain Episodes. Pediatric Blood & Cancer. 2026;73(10). doi:10.1002/1545-5017.70615

BibTeX
@article{Korman2026,
  author = {Korman, Rawan and Yasmine, Maria and Hatabah, Dunia and Alzraikat, Noor and Harris, Frank and Brown, Lou Ann and Chonat, Satheesh and Bakshi, Nitya and Rees, Chris A and Dampier, Carlton and Morris, Claudia R},
  title = {Secretory Phospholipase A 2 in Patients With Sickle Cell Disease Hospitalized for Vaso‐Occlusive Pain Episodes},
  journal = {Pediatric Blood & Cancer},
  year = {2026},
  volume = {73},
  number = {10},
  doi = {10.1002/1545-5017.70615}
}
Kostenlos starten →